C4TS Newsletter Autumn 2015 Issue 8 Welcome to the C4TS Autumn 2015 newsletter. In this edition, we outline how our research into the diagnosis and correction of abnormal clotting has progressed to a European multicentre clinical trial (iTACTIC). We highlight the investment we are making in future trauma clinicians through our expanding educational programs. Keeping an emphasis on a global outreach, we also explain more about our recent awards from the World Health Organisation (WHO) and the Tropical Health and Education Trust (THET) to extend our educational work to sub-Saharan Africa, with the help of our international MSc students. Enjoy the read & the holidays!
Improving Resuscitation in Trauma clinical care. Ultimately patients with TIC have increased blood transfusion requirements and suffer more adverse outcomes (e.g. multi organ failure).
Background In the New Year C4TS begins the targeted recruitment of 400 trauma patients across a European network of specialist centres, to a 2year randomised controlled trial entitled “Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy (iTACTIC)”. Half of all trauma deaths result from uncontrolled bleeding, with 1 in 4 of all severely injured and shocked patients developing a clotting abnormality (i.e. trauma induced coagulopathy; TIC) within minutes of injury. Many more injured patients will go on to develop different types of coagulopathy at different times during the course of their treatment, either as a result of their body’s ongoing response to trauma or as a consequence of their Centre for Trauma Sciences
Current management of these bleeding and coagulopathic patients comprises protocol-led transfusion of red blood cells, plasma and clotting product supplements. In the absence of rapid diagnostic tests, these blood products are administered to patients, ‘blind’ to the type and severity of TIC they may have, or indeed even if they do not have TIC. Conventional laboratory tests of coagulation are not presented in a clinically useful time frame, on average becoming available to the treating trauma team only after 90 minutes. So called ‘Viscoelastic Haemostatic Assay (VHA)’ systems can now provide point-of-care test results within 10 minutes.
www.c4ts.qmul.ac.uk
Professor Susan Brundage (Education Lead)
by Dr Simon Eaglestone (Head of Operations) VHA can be used to identify TIC early and to guide transfusion of blood products more effectively, by matching to that individual patient’s ongoing needs. The trial will compare the outcomes of patients treated using the conventional blood transfusion strategy versus those treated using a personalised VHA-led algorithm. Regardless of randomisation, all patients will initially receive the same local treatment, according to the best currently available evidence.
Timeline iTACTIC will recruit around 400 patients from trauma receiving hospitals in London (Royal London Hospital), Oxford, Oslo, Cologne, Amsterdam and Copenhagen. The trial will conclude at the end of 2017 and we’ll be sure to update you on the results in the Spring 2018 Newsletter!
The Trial
ClinicalTrials.gov: NCT02593877
iTACTIC is designed to find out if
More information here.
Newsletter Autumn 2015
1